RayStation achives strong presence in Japan market
The RayStation treatment planning system has generated considerable interest in Japan, a major radiation therapy market where advanced techniques are prevalent. RayStation is now well-established in the country and has a strong user base. RaySearch's distributor in Japan received 13 new RayStation orders during the third quarter of 2017.
Today, a total of 87 radiation therapy centers in Japan are using RayStation clinically. Of the new orders received, 12 were for photon planning and one was for proton planning. Japan is a major pioneer of proton therapy and RayStation has been selected as the treatment planning system in most of the recent procurements.
RayStation customers in Japan now range from leading university hospitals to smaller regional hospitals. In order to provide optimal support for this important market, RaySearch has established the wholly owned subsidiary RaySearch Japan K.K., based in Tokyo.
Takeshi Kosuga, Regional Business Director at RaySearch Japan K.K., says: “By establishing this subsidiary, we have strengthened our support for customers in Japan. There is strong demand for the RayStation treatment planning system, and the market has also expressed a great deal of interest in RayCare*, our next-generation oncology information system, which will be released in December 2017."
Johan Löf, CEO of RaySearch Laboratories, says: “I am delighted that we have been able to achieve such a strong position in Japan. Our distributor has done an excellent job of establishing RayStation in the country, and I am pleased that we can bring the unique benefits of RayStation to this important and sophisticated market.”
RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.
RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch, and which will be launched in December 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003.
To learn more about RaySearch, go to: www.raysearchlabs.com
* Subject to regulatory clearance in some markets.
For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00